Because DNMT3A and PTPN11 mutations are found in combination in AML and JMML patients, our double mutant mice provide a novel clinically relevant model for developing and evaluating therapies for myeloid leukemia. This evidence concerns the gene DNMT3A and juvenile myelomonocytic leukemia.